T-DXd and T-DM1 have been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of advanced HER2-positive breast cancer [4, 5, 29, 31], whereas DV has not been approved by these agencies. This evidence concerns the gene ERBB2 and breast carcinoma.